Dare Bioscience, Inc. (DARE) financial statements (2020 and earlier)

Company profile

Business Address 3655 NOBEL DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments578357651
Cash and cash equivalents578357651
Receivables100   
Prepaid expense100   
Other current assets  0   
Other undisclosed current assets   212
Total current assets:678377753
Noncurrent Assets
Property, plant and equipment00 110
Intangible assets, net (including goodwill)  5   
Goodwill  5   
Restricted cash and investments     0
Other noncurrent assets111000
Other undisclosed noncurrent assets     (0)
Total noncurrent assets:116111
TOTAL ASSETS:7814387853
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:211696
Accounts payable  0121
Accrued liabilities  0564
Employee-related liabilities100  1
Other undisclosed accounts payable and accrued liabilities10    
Debt0  883
Deferred revenue and credits 3  
Other liabilities     0
Other undisclosed current liabilities30   (1)
Total current liabilities:61117168
Noncurrent Liabilities
Long-term debt and lease obligation   413 
Long-term debt, excluding current maturities   413 
Liabilities, other than long-term debt100300
Deferred revenue and credits02  
Deferred rent credit 0
Other liabilities0  100
Business combination, contingent consideration, liability1     
Total noncurrent liabilities:1008130
Total liabilities:71125298
Stockholders' equity
Stockholders' equity attributable to parent0713134945
Common stock000000
Additional paid in capital453626214210167
Accumulated other comprehensive loss(0)(0)(0)   
Accumulated deficit(44)(29)(12)(201)(161)(122)
Total stockholders' equity:0713134945
TOTAL LIABILITIES AND EQUITY:7814387853

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:   1 0
Operating expenses(14)(17)(11)(38)(37)(20)
Operating loss:(14)(17)(11)(37)(37)(20)
Nonoperating income (expense)00 (2)(2)(3)
Other nonoperating income (expense)00   (3)
Interest and debt expense  (0)(2)(2)(4)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)(0)(0)   
Loss from continuing operations before income taxes:(14)(17)(12)(42)(42)(27)
Income tax expense (0)    
Net loss:(14)(17)(12)(42)(42)(27)
Other undisclosed net income attributable to parent000224
Net loss attributable to parent:(14)(17)(12)(39)(40)(23)
Preferred stock dividends and other adjustments(1)    (82)
Other undisclosed net income available to common stockholders, basic     82
Net loss available to common stockholders, diluted:(15)(17)(12)(39)(40)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(14)(17)(12)(42)(42)(27)
Comprehensive loss:(14)(17)(12)(42)(42)(27)
Other undisclosed comprehensive loss, net of tax, attributable to parent(1)(0)(0)   
Comprehensive loss, net of tax, attributable to parent:(15)(17)(12)(42)(42)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: